KRAS and pancreatic ductal adenocarcinoma: Analyzing differences in the mutational status of this THCA cell line compared to the other we noticed that CAL-62 cells carry an activating mutation in the KRAS (G12R, c.34G>C) oncogene, the third most common KRAS mutation in pancreatic ductal adenocarcinoma (PDAC) [28].